clofarabine has been researched along with Acute Biphenotypic Leukemia in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bilger, K; Blaise, D; Chevallier, P; de La Tour, RP; Delaunay, J; El-Cheikh, J; Furst, S; Guillaume, T; Labopin, M; Lioure, B; Michallet, M; Milpied, N; Mohty, M; Moreau, P; Socié, G; Tabrizi, R; Vigouroux, S | 1 |
1 trial(s) available for clofarabine and Acute Biphenotypic Leukemia
| Article | Year |
|---|---|
Results from a clofarabine-busulfan-containing, reduced-toxicity conditioning regimen prior to allogeneic stem cell transplantation: the phase 2 prospective CLORIC trial.
Topics: Adenine Nucleotides; Adult; Aged; Antilymphocyte Serum; Arabinonucleosides; Busulfan; Clofarabine; Drug Administration Schedule; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Biphenotypic, Acute; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous | 2014 |